iopofosine i 131
·Code: CLR 131
iopofosine i 131: 2 clinical trials tracked.
iopofosine i 131 evidence translation
What we can confirm
2 tracked trials
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about iopofosine i 131, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (2)
An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor
Primary endpoint: Superiority of progression free survival (PFS)
InterventionalRandomizedopen219 targetStarted 2026-12Completion 2035-01Cellectar Biosciences, Inc.
A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer
Primary endpoint: Dose Determination for CLR 125
InterventionalRandomizedopen60 targetStarted 2025-12Completion 2029-074 sites · United StatesCellectar Biosciences, Inc.